Literature DB >> 30799398

Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.

Manami Kinjo1, Tsuyoshi Yamaguchi2, Mitsuhiro Tambo2, Takatsugu Okegawa2, Hiroshi Fukuhara2.   

Abstract

BACKGROUND: Treatment of overactive bladder (OAB) with antimuscarinic agents has been shown to improve depression and/or anxiety symptoms.
OBJECTIVES: The aim of this study was to evaluate the efficacy of mirabegron on OAB symptoms and its effects on depression and/or anxiety of treatment-naïve women with OAB.
METHODS: Women treated with mirabegron were prospectively evaluated by the OAB symptom score and hospital anxiety and depression Scale before and at 4 and 8 weeks after treatment. Wilcoxon signed-rank and Spearman rank correlation coefficient were used for statistical analyses, and a p value of < 0.05 was considered as significant.
RESULTS: Of the 112 patients who were enrolled, 25.0% had been previously diagnosed as having clinical anxiety and 22.3% as having clinical depression. The OAB, anxiety, and depression symptom scores were significantly improved at both 4 and 8 weeks (p < 0.05). Anxiety, but not depression, symptoms were significantly correlated with OAB symptoms.
CONCLUSION: Improvement of OAB symptoms helps relieve anxiety, but not depression.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Anxiety; Depression; Female; Mirabegron; Overactive bladder

Year:  2019        PMID: 30799398     DOI: 10.1159/000497282

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Effects on Depression and Anxiety After Mid-Urethral Sling Surgery for Female Stress Urinary Incontinence.

Authors:  Manami Kinjo; Kazuki Masuda; Yu Nakamura; Satoru Taguchi; Mitsuhiro Tambo; Takatsugu Okegawa; Hiroshi Fukuhara
Journal:  Res Rep Urol       Date:  2020-10-19

2.  Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.

Authors:  Eliza G West; Catherine McDermott; Russ Chess-Williams; Donna J Sellers
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.